Novartis Splits Chair and CEO Positions, Names Joe Jimenez CEO
In a move that was somewhat abrupt, but hardly surprising, Novartis AG in late January announced that Joe Jimenez, who currently runs Novartis Pharma AG, would become the company's CEO, effective February 1. Long-time chairman and CEO David Vasella will remain as chairman. The announcement brings some closure to a process that began officially more than a year ago, as Novartis worked to get its succession planning right
You may also be interested in...
The Independent Beauty Association’s Akemi Ooka, head of global supply chain resources, and new board chair Elizabeth Corrigan sat down with HBW Insight to discuss ongoing supply chain challenges, how the trade association’s members are adapting, and prospects for relief ahead.
International Flavors & Fragrances looks for CEO to replace Andreas Fibig; Ultrahuman Healthcare appoints private equity expert as business chief; prebiotics developer Clasado taps nutritional scientist; Abbott kicks off nutritional partnership with Real Madrid; and CRN adjusts membership fees.
Execs told Scrip they hope to get Tyrvaya (varenicline) onto formularies and aim for pricing that would make its nasal spray competitive with Restasis and Xiidra.